Feb 24, 2025 02:00AM
Feb 12, 2025 02:00AM
Nov 19, 2024 12:52PM
Oct 10, 2024 07:02AM
Oct 10, 2024 07:00AM
Oct 7, 2024 11:36AM
Oct 7, 2024 11:30AM Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
Jun 18, 2024 03:40PM
Jun 10, 2024 02:30PM
Mar 11, 2024 02:45PM
Mar 11, 2024 02:43PM
Oct 31, 2023 09:00AM
Jun 2, 2023 12:11PM
May 22, 2023 07:40PM Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl
Mar 2, 2023 10:14AM
Nov 14, 2022 02:12AM
Nov 14, 2022 02:10AM
Aug 25, 2022 12:32PM
Jan 27, 2022 03:56PM
Jun 8, 2021 07:30AM
Feb 23, 2021 07:00AM BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary
Sep 24, 2020 02:30AM
Jul 24, 2020 10:35AM
Jul 11, 2019 05:15AM
Jun 17, 2019 02:43PM
Apr 9, 2019 06:01PM
Apr 6, 2019 08:36AM
Apr 5, 2019 08:36AM Indivior's RECOVER™ Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly Injections of SUBLOCADE™ (Buprenorphine Extended-Release) Injection w
Mar 7, 2019 10:30AM
Feb 27, 2019 08:06AM
Feb 20, 2019 09:37AM
Feb 19, 2019 08:00AM
Jan 25, 2019 01:16PM
Jan 25, 2019 01:13PM
Jan 7, 2019 07:30AM DURECT Corporation Provides Corporate Update
Dec 20, 2018 09:00AM
Dec 20, 2018 07:37AM
Dec 20, 2018 07:30AM
Dec 19, 2018 08:00AM
Dec 12, 2018 08:00AM
Nov 27, 2018 08:00AM
Nov 23, 2018 09:56AM Indivior Announces Health Canada Approval of SUBLOCADETM (Buprenorphine Extended-Release) Injection for Patients with Moderate to Severe Opioid Use Disorder
Nov 21, 2018 09:30AM
Nov 19, 2018 08:06AM
Oct 24, 2018 02:32PM
Sep 26, 2018 11:57AM
Sep 12, 2018 06:51AM
Sep 4, 2018 07:00AM
Aug 30, 2018 08:00AM DURECT Announces Receipt of $5 Million Milestone Payment from Indivior
Jul 31, 2018 08:03AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All